Reference : Treatment of migraine: update on new therapies.
Scientific journals : Article
Social & behavioral sciences, psychology : Neurosciences & behavior
Human health sciences : Neurology
http://hdl.handle.net/2268/89786
Treatment of migraine: update on new therapies.
English
MAGIS, Delphine mailto [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie CHR >]
Schoenen, Jean mailto [> >]
2011
Current Opinion in Neurology
Yes (verified by ORBi)
International
1350-7540
1473-6551
[en] PURPOSE OF REVIEW: This review provides a comprehensive selection of the latest clinical trial results in antimigraine treatment. RECENT FINDINGS: The oral calcitonine gene-related peptide antagonist telcagepant is efficacious in acute treatment. Compared to triptans, its efficacy is almost comparable but its tolerance is superior. The same is true for the 5HT-1F agonist lasmiditan, another agent devoid of vascular effects. Triptans, as other drugs, are more efficient if taken early but nonsteroidal anti-inflammatory drugs and analgesics remain useful for acute treatment, according to several meta-analyses. Single-pulse transcranial magnetic stimulation during the aura rendered more patients pain-free (39%) than sham stimulation (22%) in one study. Topiramate could be effective for migrainous vertigo, but it did not prevent transformation to chronic migraine in patients with high attack frequency. Onabotulinumtoxin A was effective for chronic migraine and well tolerated, but the therapeutic gain over placebo was modest; the clinical profile of responders remains to be determined before widespread use. Occipital nerve stimulation was effective in intractable chronic migraine with 39% of responders compared to 6% after sham stimulation. This and other neuromodulation techniques, such as sphenopalatine ganglion stimulation, are promising treatments for medically refractory patients but large controlled trials are necessary. One study suggests that outcome of patent foramen ovale closure in migraine might depend on anatomic and functional characteristics. SUMMARY: Drugs with a better efficacy or side-effect profile than triptans may soon become available for acute treatment. The future may also look brighter for some of the very disabled chronic migraineurs thanks to novel drug and neuromodulation therapies.
http://hdl.handle.net/2268/89786
10.1097/WCO.0b013e3283462c3f

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
review.pdfPublisher postprint210.53 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.